Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEMCOVAC-OM
- Development stage
- Unknown
- Lead developer
- Gennova Biopharmaceuticals
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
GEMCOVAC-OM is a thermostable, self-amplifying mRNA (samRNA) vaccine developed by Gennova Biopharmaceuticals for the prevention of COVID-19 caused by the SARS-CoV-2 Omicron variant. The vaccine encodes the spike protein of the Omicron BA.1 lineage. Unlike first-generation mRNA vaccines that require ultra-cold storage, GEMCOVAC-OM is lyophilized and stable at standard refrigeration temperatures (2-8°C), significantly lowering the logistical barriers for distribution in diverse climates. It is administered intradermally using the Tropis needle-free injection system. In June 2023, the Drug Controller General of India (DCGI) granted Emergency Use Authorization for GEMCOVAC-OM as a booster dose in adults who have completed primary vaccination with COVISHIELD or COVAXIN.
- Brand names
- GEMCOVAC-OM
- Other names
- Gennova Omicron vaccinesamRNA COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on GEMCOVAC-OM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEMCOVAC-OM.